Metabolomic biomarkers of prostate cancer: Prediction, diagnosis, progression, prognosis, and recurrence

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 6, 2016, Pages 887-906

  Kelly, Rachel S ^a,b   Heiden, Matthew G Vander ^c,d   Giovannucci, Edward ^a,b   Mucci, Lorelei A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; ALANINE; ARACHIDONIC ACID DERIVATIVE; ARGININE; BIOLOGICAL MARKER; CHOLINE; CITRIC ACID; CREATINE; CYSTATHIONINE; CYSTEINE; GLUTAMIC ACID; GLUTAMINE; HOMOCYSTEINE; INOSITOL; ISOLEUCINE; KYNURENINE; LYSINE; LYSOPHOSPHOLIPID; METHIONINE; ORNITHINE; PHOSPHORYLCHOLINE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; SPERMINE; SPHINGOMYELIN; TAURINE; TRYPTOPHAN; TUMOR MARKER; URACIL; VALINE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CELL PROLIFERATION; GOLD STANDARD; HUMAN; LIPIDOMICS; MALE; METABOLOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SECRETION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; METABOLISM; METABOLOME; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

BIOMARKERS; HUMANS; MALE; METABOLOME; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84973335045     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1223     Document Type: Review

References (109)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology 2014;28:135-42.
3. Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the prostate health index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19:1-13.
4. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 2014; 348.
5. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, et al. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget 2015;6: 16411-21.
6. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc 2010;85:77-86.
7. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012;13:1114-24.
8. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17:3903-12.
9. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
10. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004;22:245-52.
11. Holmes E, Loo RL, Stamler J, Bictash M, Yap IKS, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008;453:396-400.
12. Denkert C, Bucher E, Hilvo M, Salek R, Oresic M, Griffin J, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med 2012;4:37.
13. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2012;2:881-98.
14. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
16. McDunn JE, Li Z, Adam K-P, Neri BP, Wolfert RL, Milburn MV, et al. Metabolomic signatures of aggressive prostate cancer. Prostate 2013;73: 1547-60.
17. McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev 2012; 13:1-13.
18. Hsing AW, Sakoda LC, Chua SC. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:843S-57S.
19. Trock BJ Application of metabolomics to prostate cancer. Urol Oncol 2011;29:572-81.
20. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991;18: 25-46.
21. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002;48:155-71.
22. Mondul A, Moore S, Weinstein S, Männistö S, Sampson J, Albanes D. 1-Stearoylglycerol is associated with risk of prostate cancer: results from a serum metabolomic profiling analysis. Metabolomics 2014; 10:1036-41.
23. Mondul A, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer 2015;137:2124-32.
24. Halliday KR, Fenoglio-Preiser C, Sillerud LO. Differentiation of human tumors from nonmalignant tissue by natural-abundance 13C NMR spectroscopy. Magn Reson Med 1988;7:384-411.
25. Schiebler ML, Miyamoto KK, White M, Maygarden SJ, Mohler JL. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993;29:285-91.
26. Hahn P, Smith ICP, Leboldus L, Littman C, Somorjai RL, Bezabeh T. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra. Cancer Res 1997; 57:3398-401.
27. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-54.
28. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization ofhuman prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65:3030-4.
29. Komoroski RA, Holder JC, Pappas AA, Finkbeiner AE. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magn Reson Med 2011;65:911-3.
30. Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol 2011;11:14.
31. Brown M, McDunn J, Gunst P, Smith E, Milburn M, Troyer D, et al. Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med 2012;4:33.
32. Kami K, Fujimori T, Sato H, Sato M, Yamamoto H, Ohashi Y, et al. Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 2013;9: 444-53.
33. Li C, Han J, Yao Q, Zou C, Xu Y, Zhang C, et al. Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucleic Acids Res 2013;41:e101-e.
34. Lokhov P, Dashtiev M, Moshkovskii S, Archakov A. Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 2010;6: 156-63.
35. Cho H-J, Kim JD, Lee W-Y, Chung BC, Choi MH. Quantitative metabolic profiling of 21 endogenous corticosteroids in urine by liquid chromatography-triple quadrupole-mass spectrometry. Analytica Chimica Acta 2009;632:101-8.
36. Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem 2011;401:635-46.
37. Gamagedara S, Kaczmarek AT, Jiang Y, Cheng X, Rupasinghe M, Ma Y. Validation study of urinary metabolites as potential biomarkers for prostate cancer detection. Bioanalysis 2012;4:1175-83.
38. Zhang T, Watson DG, Wang L, Abbas M, Murdoch L, Bashford L, et al. Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS One 2013;8:e65880.
39. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age in dependent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008;68:620-8.
40. Zhou X, Mao J, Ai J, Deng Y, Roth MR, Pound C, et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS One 2012;7:e48889.
41. Zang X, Jones CM, Long TQ, Monge ME, Zhou M, Walker LD, et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. J Proteome Res 2014;13:3444-54.
42. Struck-Lewicka W, Kordalewska M, Bujak R, Yumba Mpanga A, Markuszewski M, Jacyna J, et al. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: a pilot study. J Pharm Biomed Anal 2015;111:351-61.
43. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010;5: e14175.
44. Menard C, Smith ICP, Somorjai RL, Leboldus L, Patel R, Littman C, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001;50:317-23.
45. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 2010;70:710-7.
46. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of and rogen deprivation therapy for prostate cancer. Clin Cancer Res 2012;18:3677-85.
47. Giskeodegard GF, Bertilsson H, Selnaes KM, Wright AJ, Bathen TF, Viset T, et al. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 2013;8:e62375.
48. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, et al. Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression. PLoS One 2011;6:e22486.
49. Osl M, Dreiseitl S, Pfeifer B, Weinberger K, Klocker H, Bartsch G, et al. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bio informatics 2008;24:2908-14.
50. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011;6:e24143.
51. Huang G, Liu X, Jiao L, Xu C, Zhang Z, Wang L, et al. Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer. Eur J Pharmacol 2014;729:132-7.
52. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
53. Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RWG Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res 2011;10:1361-73.
54. Liesenfeld DB, Habermann N, Owen RW, Scalbert A, Ulrich CM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev 2013;22:2182-201.
55. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-61.
56. Chadeau-Hyam M, Athersuch TJ, Keun HC, De Iorio M, Ebbels TM, Jenab M, et al. Meeting-in-the-middle using metabolic profiling - a strategy for the identification of intermediate biomarkers in cohort studies. Biomarkers 2011;16:83-8.
57. Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol 2011;7:525.
58. Xia J, Broadhurst D, Wilson M, Wishart D. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013;9:280-99.
59. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Canadian Med Assoc J 2007;176:1853-8.
60. Li T, Apte U. Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. In: James PH, editor. Advances in pharmacology: Academic Press; 2015. p. 263-302.
61. Currie E, Schulze A, Zechner R, Walther Tobias C, Farese Jr Robert V. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18: 153-61.
62. Soronen P, Laiti M, Torn S, Härkönen P, Patrikainen L, Li Y, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92:281-6.
63. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Fut Oncol 2010;6:1863-81.
64. Hosios AM, Vander Heiden MG Acetate metabolism in cancer cells. Cancer Metab 2014;2:27.
65. Medina MA Glutamine and cancer. TJ Nutr 2001;131:S2539-S42.
66. Yang P, Cartwright CA, Li JIN, Wen S, Prokhorova IN, Shureiqi I, et al. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 2012;41:1495-503.
67. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, et al. Insulin resistance and cancer: the role ofinsulin and IGFs. Endocr Rel Cancer 2013;20:R1-R17.
68. Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, et al. Sarcosine as a potential prostate cancer biomarker-a review. Int J Mol Sci 2013;14:13893-908.
69. Zhang A, Sun H, Yan G, Wang P, Han Y, Wang X. Metabolomics in diagnosis and biomarker discovery of colorectal cancer. Cancer Lett 2014;345:17-20.
70. Ni Y, Xie G, Jia W. Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res 2014;13:3857-70.
71. Jayavelu ND, Bar NS. Metabolomic studies of human gastric cancer: review. World J Gastroenterol 2014;20:8092-101.
72. Antonowicz S, Kumar S, Wiggins T, Markar SR, Hanna GB. Diagnostic metabolomic blood tests for endoluminal gastrointestinal cancer-a systematic review and assessment of quality. Cancer Epidemiol Biomarkers Prev 2016;25:6-15.
73. Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao Y-T, et al. Plasma metabolite biomarkers for the detection of pancreatic cancer. J Proteome Res 2015;14:1195-202.
74. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development. Nat Med 2014;20: 1193-8.
75. Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, Cantley LC, et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 2013;31:522-9.
76. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84.
77. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009;69:4918-25.
78. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 2012;7:e40459.
79. 1H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer 2013; 12:121.
80. Rocha CM, Barros AS, Goodfellow BJ, Carreira IM, Gomes A, Sousa V, et al. NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 2015;36:68-75.
81. Abbassi-Ghadi N, Kumar S, Huang J, Goldin R, Takats Z, Hanna GB. Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer 2013;49:3625-37.
82. Song H, Wang L, Liu HL, Wu XB, Wang HS, Liu ZH, et al. Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity. Oncol Rep 2011;26:431-8.
83. Wiggins T, Kumar S, Markar SR, Antonowicz S, Hanna GB. Tyrosine, phenylalanine, and tryptophan in gastroesophageal malignancy: a systematic review. Cancer Epidemiol Biomarkers Prev 2015;24:32-8.
84. Beger R. A review of applications of metabolomics in cancer. Metabolites 2013;3:552.
85. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, et al. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer 2012; 130:2791-800.
86. Wen H, Yoo SS, Kang J, Kim HG, Park J-S, Jeong S, et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 2010;52:228-33.
87. Vineis P, Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 2007;16:1954-65.
88. Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, Viano J, Angulo JC, Gonzalez J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magn Reson Imaging 1999;17:755-65.
89. Krug S, Kastenmuller G, Stuckler F, Rist MJ, Skurk T, Sailer M, et al. The dynamic range of the human metabolome revealed by challenges. FASEB J 2012;26:2607-19.
90. Gieger C, Geistlinger L, Altmaier E, Hrabé de Angelis M, Kronenberg F, Meitinger T, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008;4: e1000282.
91. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol 2010;5:4-17.
92. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
93. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012;14:365-74.
94. Morris C, O'Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, et al. The relationship between BMI and metabolomic profiles: a focus on amino acids. Proc Nutr Soc 2012;71:634-8.
95. Menni C, Kastenmuller G, Petersen AK, Bell JT, Psatha MTsai PC, et al. et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol 2013; 42:111-9.
96. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
97. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3-13.
98. Wyatt AW, Mo F, Wang Y, Collins CC. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl 2013;15:301-8.
99. Centers for Disease Control and Prevention. Prostate cancer rates by race and ethnicity; 2014 [cited 2015 Feb 27. Available from: http://www.cdc.gov/cancer/prostate/statistics/race.htm.
100. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. Creactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95:961-2.
101. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence forthe U.S. preventive services task force. Ann Intern Med 2011;155:762-71.
102. Bictash M, Ebbels TM, Chan Q, Loo RL, Yap IKS, Brown IJ, et al. Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol 2010;63:970-9.
103. Ritchie S, Ahiahonu P, Jayasinghe D, Heath D, Liu J, Lu Y, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010;8:13.
104. Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppänen Laakso T, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011;71:3236-45.
105. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 2012;11:4361-72.
106. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K, Ballas RA, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010;70:8309-18.
107. Kyrtopoulos SA Making sense of OMICS data in population-based environmental health studies. Environ Mol Mutagen 2013;54:468-79.
108. Schalken JA Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010;58:19-20.
109. Wu C-L, Jordan KW, Ratai EM, Sheng J, Adkins CB, DeFeo EM, et al. Metabolomic imaging for human prostate cancer detection. Sci Translat Med 2010;2:16ra8-ra8.